Combination of Hemodialysis and Hemoperfusion for the Treatment of End-Stage Chronic Kidney Disease Patients and Its Impact on Microinflammatory Response and Renal Function
JIAO Lijuan, WANG Ting, LI Yuanyuan, et al
The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Urumqi 830054, China
Abstract：Objective: To observe the effects of the combination of hemodialysis and hemoperfusion on micro inflammatory response and renal function in end-stage patients with chronic kidney disease (CKD). Methods: Ninety end-stage CKD patients admitted to our hospital from May 2020 to May 2022 were randomly assigned into an observation group and a control group (45 patients in each group).The control group received only hemodialysis treatment,while the observation group received combined hemoperfusion therapy in addition to hemodialysis.After the treatment,calcium and phosphorus metabolism indicators,renal function,microinflammatory response,and oxidative stress response were compared between the two groups. Results: After 6 months of treatment, the blood phosphorus and calcium phosphorus product levels in the observation group were lower than those in the control group [(1.24±0.29) mmoL/L ratio (1.85 ± 0.20) mmoL/L, (2.49±0.53) mmoL2/L2 ratio (3.75±0.59) mmoL2/L2], with a significant difference (P<0.05), while there was no significant difference (P>0.05) in blood calcium levels between the two groups [(2.01±0.41) mmoL/L ratio (2.03±0.47) mmoL/L]. The levels of UA, Scr, and BUN in the observation group were lower than those in the control group [(319.74±23.73)] μmoL/L ratio (376.25±25.86) μmoL/L, (244.06±16.35) μmoL/L ratio (286.59±20.82) μmoL/L and (15.87±4.26) mmoL/L was statistically significant (P<0.05) compared to (21.74±5.74) mmoL/L. Observation group micro inflammatory index TNF- α, The levels of IL-6 and hs CRP in the control group were lower than those in the control group [(75.15±6.02) ng/L ratio (80.82±6.51) ng/L, (25.48±4.65) ng/L ratio (31.29±5.28) ng/L, (6.24±2.05) mg/L ratio (9.87±2.24) mg/L], with statistically significant differences (P<0.05). The SOD level in the observation group was higher than that in the control group ](73.54±7.28) U/mL vs (66.29±6.87) U/mL], with a significant difference (P<0.05); The levels of MDA and MPO in the observation group were lower than those in the control group [(8.36±2.46) nmoL/mL vs (10.84±2.73) nmoL/mL, (56.29±5.29) U/L vs (61.74±6.73) U/L], with significant differences (P<0.05). Conclusion: The combination of hemodialysis and hemoperfusion for end-stage CKD patients is beneficial for regulating calcium and phosphorus metabolism,protecting renal function,and has a relatively small impact on microinflammatory status and oxidative stress response.This approach has significant clinical value.
焦丽娟, 王婷, 李媛媛, 帕热旦木·托乎提, 杨文君. 血液透析联合血液灌流治疗慢性肾脏病终末期患者及对微炎症反应肾功能的影响[J]. 河北医学, 2023, 29(11): 1832-1837.
JIAO Lijuan, WANG Ting, LI Yuanyuan, et al. Combination of Hemodialysis and Hemoperfusion for the Treatment of End-Stage Chronic Kidney Disease Patients and Its Impact on Microinflammatory Response and Renal Function. HeBei Med, 2023, 29(11): 1832-1837.
[1] 何传梅,刘锦秀,李慧,等.高压氧辅助血液透析联合灌流治疗对终末期糖尿病肾病患者肾功能及免疫炎性因子的影响[J].中华航海医学与高气压医学杂志,2021,28(4):460-463. [2] 李京,王怡,李霞.血液透析联合血液灌流治疗对慢性肾病患者钙磷和脂质代谢的影响[J].重庆医学,2020,49(9):1409-1412. [3] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34. [4] 单彩娣,单薇,徐晓琳,等.海昆肾喜胶囊联合氯沙坦钾片治疗慢性肾脏病患者疗效观察及对肾功能和炎性因子的影响[J].中国医师进修杂志,2022,45(4):344-347. [5] 陈鸿钰,黎芳名,曾丽梅.血液灌流联合血液透析与血液透析滤过治疗老年慢性肾功能不全的疗效分析[J].临床肾脏病杂志,2021,21(7):529-534. [6] Danese M D,Lubeck D,Belozeroff V,et al.Real world use and effects of calcimimetics in treating mineral and bone disorder in hemodialysis patients[J].American journal of nephrology,2020,51(10):815-822. [7] 宋新宇,马飞.血液透析和腹膜透析对终末期肾病患者的影响[J].中国卫生标准管理,2022,13(14):72-77. [8] Lee Y J,Li K Y,Wang P J,et al.Alleviating chronic kidney disease progression through modulating the critical genus of gut microbiota in a cisplatin-induced Lanyu pig model[J].2020,28(1):103-114. [9] 吴光彪.血液透析联合血液灌流治疗慢性肾脏病矿物质和骨异常患者的效果评价[J].实用临床医药杂志,2020,24(10):110-112. [10] Theodorakopoulou M,Loutradis C,Bikos A,et al.The effects of nebivolol and irbesartan on ambulatory aortic blood pressure and arterial stiffness in hemodialysis patients with intradialytic hypertension[J].Blood Purification,2020,50(1):1-11.
2023, Vol. 29 
冀公网安备13080202000677号